Anti-TNF alpha in dermatology;Anti-TNF alpha en dermatologie

Annales de Dermatologie et de Venereologie

Volumn 129, Issue 12, 2002, Pages 1374-1379

  Mahe, E ^a   Descamps, V ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

BEHCET DISEASE; BULLOUS DERMATITIS; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TOXIC EPIDERMAL NECROLYSIS;

HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; NEOPLASM PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SKIN DISEASES; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036920922     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
2. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
3. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
4. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2004;121:1088-9.
5. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001;137:930-3.
6. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323-6.
7. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587-9.
8. Griffiths CE. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 2002;359:279-80.
9. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
10. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
11. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001;26:27-9.
12. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;146:118-21.
13. Girolomoni G, Abeni D. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch Dermatol 2001;137:784-5.
14. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002;46:113-5.
15. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford) 2001;4:473-4.
16. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis N. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001;358:295-6.
17. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001;358:1644.
18. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002;146:705-18.
19. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse anti-TNFalpha antibody. Bone Marrow Transplant 2001;28:47-9.
20. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002;73:665-74.
21. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001;137:1571-4.
22. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001;135:27-31.
23. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
24. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. A recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept. Arch Dermatol 2001;137:893-9.
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
26. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8.
27. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
28. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579-80.
29. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002;41:116-7.
30. Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH. Etanerceptinduced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2001;40:1317-9.
31. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-6.